Urban Emmenegger

11.9k total citations
150 papers, 3.4k citations indexed

About

Urban Emmenegger is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Urban Emmenegger has authored 150 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pulmonary and Respiratory Medicine, 81 papers in Oncology and 39 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Urban Emmenegger's work include Prostate Cancer Treatment and Research (81 papers), Radiopharmaceutical Chemistry and Applications (32 papers) and Cancer Treatment and Pharmacology (21 papers). Urban Emmenegger is often cited by papers focused on Prostate Cancer Treatment and Research (81 papers), Radiopharmaceutical Chemistry and Applications (32 papers) and Cancer Treatment and Pharmacology (21 papers). Urban Emmenegger collaborates with scholars based in Canada, United States and United Kingdom. Urban Emmenegger's co-authors include Robert S. Kerbel, Shan Man, Yuval Shaked, Giulio Francia, Francesco Bertolini, K Neftel, Daniel J. Hicklin, Yaacov Ben‐David, Ping Xu and Guido Bocci and has published in prestigious journals such as Nature, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Urban Emmenegger

143 papers receiving 3.3k citations

Peers

Countries citing papers authored by Urban Emmenegger

Since Specialization

Citations

This map shows the geographic impact of Urban Emmenegger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urban Emmenegger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urban Emmenegger more than expected).

Fields of papers citing papers by Urban Emmenegger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urban Emmenegger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urban Emmenegger. The network helps show where Urban Emmenegger may publish in the future.

Co-authorship network of co-authors of Urban Emmenegger

This figure shows the co-authorship network connecting the top 25 collaborators of Urban Emmenegger. A scholar is included among the top collaborators of Urban Emmenegger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urban Emmenegger. Urban Emmenegger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety. 2025 ·Journal of Clinical Oncology ·Alan H. Bryce, Ray McDermott, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Joel Roger Gingerich, Elias Pintus, Srikala S. Sridhar, Richard Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nolè, (unknown), Wassim Abida, (unknown), Darrin Despain, Charles J. Ryan, Karim Fizazi, Simon Chowdhury	3
2	Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer 2024 ·SHILAP Revista de lepidopterología ·(unknown), Hon S. Leong, (unknown), Xiaoyong Huang, (unknown), Urban Emmenegger, Michelle R. Downes, Paul C. Boutros, Thomas Kislinger, Stanley K. Liu	2
3	Falls in older adults during treatment for metastatic castration-resistant prostate cancer 2024 ·Journal of Geriatric Oncology ·(unknown), Narhari Timilshina, George Tomlinson, Helen Yang, (unknown), Urban Emmenegger, Shabbir M.H. Alibhai	2
4	Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus 2024 ·Cancers ·Kori Leblanc, (unknown), George Dranitsaris, Darryl P. Leong, Marc Carrier, Shawn Malone, Ricardo Rendon, (unknown), (unknown), Paweł Zalewski, Michelle Wang, Urban Emmenegger	0
5	Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial 2024 ·European Urology Oncology ·Fred Saad, Andrew J. Armstrong, (unknown), Karina Vianna, Mustafa Özgüroğlu, Craig Gedye, Gary L. Buchschacher, Ji Youl Lee, Urban Emmenegger, Jiří Navrátil, Juan Antonio Virizuela, (unknown), Denis Maillet, Hiroji Uemura, Jeri Kim, (unknown), Laura Barker, Arnold Degboe, Noel W. Clarke	7
6	Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy 2023 ·Clinical Genitourinary Cancer ·(unknown), (unknown), (unknown), (unknown), Frank Lyons, Michael Hardisty, Cari Whyne, Martin Smoragiewicz, (unknown), (unknown), Urban Emmenegger	3
7	Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer 2023 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), (unknown), Anil Kapoor, Paweł Zalewski, Neil Fleshner, Edward Chow, Urban Emmenegger	5
8	Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning 2023 ·Genes ·(unknown), Alex Kiss, (unknown), Katarzyna J. Jerzak, Sonal Gandhi, Fang‐I Lu, Urban Emmenegger, (unknown), Andrew Lagree, (unknown), (unknown), (unknown), (unknown), (unknown), Jonathan Klein, (unknown), Alex Shenfield, Ali Sadeghi‐Naini, William T. Tran	3
9	625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update 2020 ·Annals of Oncology ·Loı̈c Mourey, Henry Jacob Conter, Neal D. Shore, William L. Berry, Peter C.C. Fong, Josep M. Piulats, Leonard J. Appleman, (unknown), Gwénaëlle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Johann S. de Bono, Audrey E. Kam, Urban Emmenegger, Hao‐Hua Wu, Ping Qiu, Charles Schloss, Evan Y. Yu	4
10	620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update 2020 ·Annals of Oncology ·Emanuela Romano, Srikala S. Sridhar, Michael Kolinsky, Gwénaëlle Gravis, Loı̈c Mourey, Josep M. Piulats, William L. Berry, Howard Gurney, Margitta Retz, Leonard J. Appleman, Martin Boegemann, Johann S. de Bono, Anthony M. Joshua, Urban Emmenegger, Henry Jacob Conter, Brigitte Laguerre, (unknown), Ping Qiu, Charles Schloss, Evan Y. Yu	3
11	What Is Oligometastatic Prostate Cancer? 2019 ·European Urology Focus ·Michael Fraser, Bridget F. Koontz, Urban Emmenegger, Gert De Meerleer, Vincent Khoo, Felix Y. Feng, Niall M. Corcoran, Christopher M. Hovens, Phuoc T. Tran, Piet Ost, Paul C. Boutros	22
12	Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study 2017 ·Urology ·Christopher J.D. Wallis, Raj Satkunasivam, Refik Saskin, (unknown), Girish S. Kulkarni, Urban Emmenegger, Robert K. Nam	10
13	Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers 2016 ·Cancer Research ·Florence T.H. Wu, Shan Man, Ping Xu, Annabelle Chow, Marta Pàez‐Ribes, Christina R. Lee, Steven Pirie‐Shepherd, Urban Emmenegger, Robert S. Kerbel	45
14	Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. 2015 ·PubMed ·Leigha Rowbottom, Jordan A. Stinson, Rachel McDonald, Urban Emmenegger, Susanna Y. Cheng, Julia Lowe, Angie Giotis, (unknown), Ronald Chow, Mark Pasetka, Nemica Thavarajah, Natalie Pulenzas, Edward Chow, Carlo DeAngelis	20
15	miRNA-95 Mediates Radioresistance in Tumors by Targeting the Sphingolipid Phosphatase SGPP1 2013 ·Cancer Research ·Xiaoyong Huang, Samira Taeb, Sahar Jahangiri, Urban Emmenegger, (unknown), Jeff Bruce, Aruz Mesci, (unknown), Danny Vesprini, C. Shun Wong, Robert G. Bristow, Fei‐Fei Liu, Stanley K. Liu	125
16	Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts 2009 ·Clinical Cancer Research ·Giulio Francia, Shan Man, (unknown), Christina R. Lee, Ping Xu, Miriam E. Mossoba, Urban Emmenegger, Jeffrey A. Medin, Robert S. Kerbel	33
17	Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines 2008 ·Molecular Cancer Therapeutics ·Giulio Francia, Urban Emmenegger, Christina R. Lee, Yuval Shaked, (unknown), Miriam E. Mossoba, Jeffrey A. Medin, Shan Man, Zhenping Zhu, Larry Witte, Robert S. Kerbel	21
18	Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia 2006 ·Cancer Research ·Marcela Franco, Shan Man, (unknown), Urban Emmenegger, Yuval Shaked, Alison Cheung, Allison S. Brown, Daniel J. Hicklin, F. Stuart Foster, Robert S. Kerbel	126
19	Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy 2005 ·Cancer Research ·Yuval Shaked, Urban Emmenegger, Giulio Francia, (unknown), Christina R. Lee, Shan Man, (unknown), Yaacov Ben‐David, Robert S. Kerbel	100
20	Inflammation, Capillary Leakage and Healing of Experimental Gastric Ulcers in the Rat 1991 ·Digestion ·(unknown), Katja Ott, Urban Emmenegger, (unknown), (unknown), F Halter	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact